Cargando…
The effect of Lactobacillus reuteri supplementation in Helicobacter pylori infection: a placebo-controlled, single-blind study
BACKGROUND: Helicobacter pylori is the major cause of chronic gastritis, and considered as a risk factor for peptic ulcer and gastric cancer. The H. pylori standard antibiotic therapy fails in about 25–30% of cases, particularly because of the increasing occurrence of resistance to antibiotics. The...
Autores principales: | Buckley, Martin, Lacey, Sean, Doolan, Andrea, Goodbody, Emily, Seamans, Kelly |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7050722/ https://www.ncbi.nlm.nih.gov/pubmed/32153909 http://dx.doi.org/10.1186/s40795-018-0257-4 |
Ejemplares similares
-
Impact of Lactobacillus reuteri Supplementation on Anti-Helicobacter pylori Levofloxacin-Based Second-Line Therapy
por: Ojetti, Veronica, et al.
Publicado: (2012) -
Lactobacillus reuteri versus triple therapy for the eradication of Helicobacter pylori in functional dyspepsia
por: Muresan, Iulia Antonia Pop, et al.
Publicado: (2019) -
Inclusion of Lactobacillus Reuteri in the Treatment of Helicobacter pylori in Sardinian Patients: A Case Report Series
por: Dore, Maria P., et al.
Publicado: (2016) -
Investigating the effect of quadruple therapy with Saccharomyces boulardii or Lactobacillus reuteri strain (DSMZ 17648) supplements on eradication of Helicobacter pylori and treatments adverse effects: a double-blind placebo-controlled randomized clinical trial
por: Naghibzadeh, Nooshin, et al.
Publicado: (2022) -
Non-Viable Lactobacillus reuteri DSMZ 17648 (Pylopass™) as a New Approach to Helicobacter pylori Control in Humans
por: Mehling, Heidrun, et al.
Publicado: (2013)